As interest rates fall, business development companies', or BDCs, return on equity will likely be pressured. Oppenheimer ...
Christopher Nolan’s Oppenheimer was that rare movie that was both a box office hit and a serious award winner. It also had ...
(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...
A popular theory frequently utilized by technical analysts suggests U.S. stocks could be headed for one last leg higher over ...
Oppenheimer called the expected M&A rebound under the Trump administration “delayed or cancelled” and downgraded to "perform" ...
Oppenheimer said on Wednesday it no longer expects growth in U.S. investment banking revenue this year and slashed its ...
Oppenheimer lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $10 from $18 and keeps an Outperform rating on the shares ...
Oppenheimer upgraded The Mosaic Company (NYSE:MOS) to Outperform from Perform and set a price target of $33 given the fertilizer maker’s efforts to reduce costs, optimize its product portfolio, and ...
Christopher Nolan’s Oppenheimer was that rare movie that was both a box office hit and a serious award winner. It also had one of the most incredibly stacked casts in recent memory. Jack Quaid ...